This article serves as a clinical adjunct and reference document for doctors in attendance at my February 26, 2026 session at Parker Seminars, Las Vegas.
The imperative for a systems-biology approach.
The clinical management of neurological decline — from peripheral neuropathies to central neurodegeneration — represents one of the most profound challenges in modern medicine. Conventional models view the nervous system through a static lens, focusing on symptomatic management (gabapentinoids, antidepressants) rather than addressing the upstream biological failures that precipitate neuronal death.
The emerging consensus supports a paradigm shift toward "restorative neurology" — predicated on the understanding that the nervous system retains significant plasticity and regenerative potential, provided the biological terrain is conducive to repair.
This framework rejects the reductionist "one drug, one target" model in favor of a layered, hierarchical strategy that mirrors the complexity of neuronal physiology.
The framework is built on three pillars: precise etiological stratification, restoration of the bioenergetic baseline, and targeted induction of regenerative signaling pathways.
The etiological triad.
Mechanical insults
Mechanical neuropathies — entrapment, radiculopathy, traumatic transection — initiate a cascade of degenerative events. Wallerian degeneration of the distal segment is necessary for repair, but chronic compression leads to sustained inflammation that becomes maladaptive (TNF-α, IL-1β sensitize nociceptors). Compression of the vasa nervorum causes local hypoxia and ATP failure; reperfusion generates ROS, compounding the injury.
Metabolic insults
Diabetic peripheral neuropathy is the most prevalent form. In hyperglycemia, glucose is shunted into the polyol pathway, depleting NADPH and collapsing glutathione defense. Advanced glycation end-products (AGEs) accumulate in the vasa nervorum, binding RAGE and triggering chronic NF-κB inflammation. Central insulin resistance ("Type 3 Diabetes") drives parallel neurodegeneration in the brain.
Toxic insults
Chemotherapy-induced peripheral neuropathy varies by drug class:
- Taxanes stabilize microtubules, freezing axonal transport → "dying back" neuropathy.
- Vinca alkaloids prevent microtubule assembly → similar collapse of transport.
- Platinum compounds form DNA adducts in dorsal root ganglia → sensory neuronopathy.
Heavy metals (Pb, Hg, As) bind sulfhydryl groups, blocking key enzymes; transition metals catalyze Fenton chemistry, producing hydroxyl radicals that peroxidize myelin.
Phase 1: Establishing the metabolic foundation.
Ketogenic nutrition
Beyond fuel, beta-hydroxybutyrate (BHB) directly inhibits the NLRP3 inflammasome, reducing IL-1β and IL-18 maturation. Ketones produce a higher ATP-to-oxygen ratio with fewer ROS. The KD activates the SIRT1/AMPK/PGC-1α axis, driving mitochondrial biogenesis.
Alpha-lipoic acid (ALA)
Functions in both aqueous and lipid environments. Regenerates vitamin C, vitamin E, and glutathione. Activates insulin signaling and GLUT4 translocation. Improves nitric-oxide–mediated vasodilation of the vasa nervorum. Multiple RCTs (ALADIN, SYDNEY, NATHAN 1) show significant reduction in Total Symptom Score in DPN at 600 mg IV.
Berberine
A robust activator of AMPK — inhibits mTOR, triggers autophagy, clears damaged mitochondria. Downregulates HMGB1/TLR4/NF-κB. In rat sciatic nerve injury models, 20 mg/kg accelerates remyelination and motor recovery — distinct from its hypoglycemic effects.
Phase 2: Mitochondrial resuscitation and detoxification.
Metallothionein (MT) — the inducible heavy-metal shield
Low-molecular-weight, cysteine-rich proteins with extraordinarily high affinity for Hg, Cd, and Pb. Their thiol clusters react with hydroxyl radicals at ~300× the rate of glutathione. Zinc is the primary physiologic inducer of MT via the MTF-1 transcription factor — supplementation enhances detoxification capacity.
Glutathione (GSH)
GSTs conjugate GSH to xenobiotics and heavy metals for excretion. In platinum-induced neuropathy, GSH reduces platinum accumulation in dorsal root ganglia. Oral has poor bioavailability — IV, liposomal, or NAC precursor is preferred.
Methylene blue — the electron cycler
A unique hormetic drug. In damaged mitochondria, Complex I and III leak electrons; MB accepts electrons from NADH and transfers them directly to Cytochrome C, bypassing dysfunction and restoring ATP. Low doses (0.5–4 mg/kg) enhance respiration and memory; high doses inhibit ETC.
NAD+
Critical coenzyme for glycolysis, Krebs cycle, sirtuins, and PARPs. Systemically depleted in injury and aging. Synergizes with MB, which converts NADH back to NAD+.
Mitochondrial peptides
- SS-31 (Elamipretide) — binds cardiolipin on the inner mitochondrial membrane, stabilizing ETC supercomplexes and preventing mPTP opening.
- MOTS-c — mitochondrial-derived peptide that translocates to the nucleus, enhances whole-body insulin sensitivity and glucose uptake (mimics exercise).
Phase 3: Botanical neurotrophics — Hericium erinaceus.
Lion's Mane contains hericenones (fruiting body) and erinacines (mycelium) — bioactive diterpenoids that cross the blood-brain barrier.
Mechanisms:
- Endogenous NGF synthesis — Unlike exogenous NGF (which cannot cross the BBB), H. erinaceus compounds stimulate the brain's own NGF production from astrocytes.
- Direct neurite outgrowth — Erinacine S promotes neurite outgrowth via neurosteroid accumulation.
- Peripheral nerve regeneration — In crush-injury models, H. erinaceus significantly accelerates axonal regeneration and motor recovery.
- Signaling — Mediated through ERK1/2 and PI3K/Akt pathways.
Phase 4: The concentration gradient — high-dose vitamin B12.
The premise of high-dose B12 therapy lies in pharmacokinetics. Under normal conditions, B12 absorption is rate-limited by Intrinsic Factor and Transcobalamin II — both saturable.
When B12 is administered parenterally at high doses (1,000–5,000 mcg+), serum levels spike to supraphysiological concentrations, overwhelming specific transport and forcing entry via mass-action passive diffusion.
This creates a massive concentration gradient that "seeps" B12 into nerve tissue even in the presence of receptor defects.
Methylcobalamin — the active regenerator
The preferred form for neurological repair. Accumulates in spinal cord and peripheral nerves more than other forms. Facilitates conversion of homocysteine to methionine → SAMe → phosphatidylcholine (myelin) and methylation of Myelin Basic Protein.
The Immediate Early Gene (IEG) response
High-dose MeCbl is not just substrate provision — it's a signaling event. It modulates IEGs like c-Fos, transcription factors that govern downstream "late response" genes for plasticity and growth. The cascade leads to BDNF, NGF, and cytoskeletal proteins for axonal extension.
Kinase activation: Erk1/2 and Akt
MeCbl increases the activity of two critical signaling kinases:
- Akt — potent survival signal that inhibits apoptosis.
- Erk1/2 — governs cellular differentiation and neurite outgrowth. In Schwann cells, MeCbl-mediated Erk1/2 signaling promotes differentiation and Myelin Basic Protein expression, accelerating remyelination.
Inhibition of ER stress
Injury causes accumulation of misfolded proteins in the endoplasmic reticulum, triggering the Unfolded Protein Response and apoptosis (via CHOP, Caspase-12). B12 downregulates GRP78 and CHOP, preserving the neuronal pool — a prerequisite for functional recovery.
A unified clinical hierarchy.
- Diagnose — Mechanical, metabolic, or toxic?
- Restore the metabolic terrain — Ketogenic state, ALA, berberine.
- Resuscitate mitochondria — Zinc/MT, glutathione, methylene blue, NAD+, SS-31/MOTS-c.
- Activate neurotrophics — Hericium erinaceus.
- Drive direct repair — High-dose methylcobalamin to create the concentration gradient, activate IEGs, inhibit ER stress, and drive remyelination via Schwann cell differentiation.
This comprehensive approach addresses the injury from the systemic metabolic environment down to the transcriptional regulation of the neuron. By treating the "metabolic reality" and leveraging the specific pharmacodynamics of neurotrophic agents, the clinician can transition the patient from a state of neurodegeneration to one of neuroregeneration.
